JPH0662632B2 - Novel antibiotic A1-R2397 substance and its production method - Google Patents

Novel antibiotic A1-R2397 substance and its production method

Info

Publication number
JPH0662632B2
JPH0662632B2 JP61171759A JP17175986A JPH0662632B2 JP H0662632 B2 JPH0662632 B2 JP H0662632B2 JP 61171759 A JP61171759 A JP 61171759A JP 17175986 A JP17175986 A JP 17175986A JP H0662632 B2 JPH0662632 B2 JP H0662632B2
Authority
JP
Japan
Prior art keywords
substance
culture
methanol
antibiotic
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP61171759A
Other languages
Japanese (ja)
Other versions
JPS6330492A (en
Inventor
吉和 佐藤
成貴 石井
慎二 宮道
美恵子 長沢
喬 庄村
正次 瀬崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Priority to JP61171759A priority Critical patent/JPH0662632B2/en
Publication of JPS6330492A publication Critical patent/JPS6330492A/en
Publication of JPH0662632B2 publication Critical patent/JPH0662632B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Description

【発明の詳細な説明】 産業上の利用分野 本発明は抗腫瘍活性及び抗菌活性を有する新抗生物質Al
-R2397物質及びその製造法に関するものである。
The present invention relates to a new antibiotic Al having antitumor activity and antibacterial activity.
-R2397 substance and its manufacturing method.

従来の技術及び発明が解決しようとする問題点 従来、数多くの抗生物質が発明され、医薬品、動物用薬
品、農薬等の分野で実用化されている。しかしながら、
まだ有効な物質が見出されないため解決されていない医
療あるいは産業分野が多く残されている。たとえば癌化
学療法分野においても、新しい作用をもつ新規の抗腫瘍
性抗生物質を提供することは常に要望されている。
2. Description of the Related Art Conventional techniques and problems to be solved by the invention Many antibiotics have been invented and put to practical use in the fields of medicines, veterinary medicines, agricultural chemicals and the like. However,
There are many medical or industrial fields that have not been solved because no effective substances have been found yet. For example, also in the field of cancer chemotherapy, it is always desired to provide a novel antitumor antibiotic having a new action.

本発明者らは以上のような点に着目し、新規な抗腫瘍性
抗生物質を提供するとともに、その製造法を確立するこ
とによって、これを解決しようとするものである。
The present inventors pay attention to the above points, and provide a novel antitumor antibiotic, and try to solve this by establishing a manufacturing method thereof.

問題点を解決するための手段 本発明者らは、上述の期待にこたえるべく、抗腫瘍活性
を有する物質の探索を続けていたところ、サーモモノス
ポラ属に属するある菌株の培養物中にマウス白血病細胞
(P-388)に対する細胞障害活性その他の抗腫瘍活性及び
抗菌活性を有する物質が生産されていることを見い出
し、有効物質Al-R2397物質を単離し、その理化学的性状
及び生物学的性状を確定し、さらにX線結晶回析によ
り、その構造を確立することにより本発明を完成した。
したがって、第一の本発明は、下記の(I)式で表わされ
る新規抗腫瘍性抗生物質Al-R2397物質を提供するもので
ある。
Means for Solving the Problems The inventors of the present invention continued to search for a substance having antitumor activity in order to meet the above-mentioned expectations, and found that mouse leukemia was found in a culture of a strain belonging to the genus Thermomonospora. cell
(P-388) was found to have produced a substance having cytotoxicity and other antitumor and antibacterial activities, and the active substance Al-R2397 was isolated and its physicochemical and biological properties were determined. Then, the present invention was completed by establishing its structure by X-ray crystal diffraction.
Therefore, the first aspect of the present invention provides a novel antitumor antibiotic Al-R2397 substance represented by the following formula (I).

さらに第二の本発明は、サーモモノスポラ属に属する抗
生物質Al-R2397物質生産菌を培養しその培養物から抗生
物質Al-R2397物質を採取することを特徴とする抗生物質
Al-R2397物質の製造法を提供するものである。
Furthermore, the second present invention is an antibiotic characterized by culturing an antibiotic Al-R2397 substance-producing bacterium belonging to the genus Thermomonospora and collecting the antibiotic Al-R2397 substance from the culture.
A method for producing an Al-R2397 substance is provided.

Al-R2397物質と類似の構造をもつ化合物として谷田ら
(S.Tanida et al.J.Antibiotics,Vol.34,489 1981)によ
り、ノカルディアの一種とみられる微生物の代謝産物中
から単離されたアンサマイトシン群化合物が挙げられる
が、Al-R2397物質はこれらのいずれとも異なり、新規物
質と判定した。
As a compound with a structure similar to the Al-R2397 substance Yata et al.
(S. Tanida et al. J. Antibiotics, Vol.34, 489 1981), an ansamitocin group compound isolated from metabolites of a microorganism that is considered to be a kind of Nocardia, but Al-R2397 substance is Different from any of the above, it was determined to be a new substance.

本発明に使用されるAl-R2397物質生産菌の一例として
は、本発明者らによりインド国の土壌より新たに分離さ
れたAl-R2397株がある。Al-R2397株の菌学的性状は、次
の通りである。
An example of the Al-R2397 substance-producing bacterium used in the present invention is Al-R2397 strain newly isolated from the soil of India by the present inventors. The mycological properties of the Al-R2397 strain are as follows.

I.形態 基生菌糸は、よく伸長分岐し、通常分断しない。一般に
気菌糸の着生は少なく、チロシン寒天、グリセロール・
アスパラギン寒天上などで、わずかに気菌糸の着生が認
められる。気菌糸の分岐は単純分岐で車軸分岐は認めら
れない。
I. Morphology The basal hyphae are well-extended and branched, and usually do not divide. In general, aerial hyphae do not grow much, and tyrosine agar, glycerol
Slight aerial mycelial colonization is observed on asparagine agar. The aerial mycelium branches are simple branches, and no axle branch is observed.

胞子の着生は極めて限られた条件でしか確認されておら
ず、例えば4分の1濃度に希釈したチロシン寒天で生育
した気菌糸上に28℃、約1ヶ月培養後、緑色の単胞子性
胞子を集合して着生した。胞子の大きさは直径1.0〜1.2
ミクロンのほぼ球形で、表面は平滑、運動性は認められ
ず、100℃煮沸水中での生存試験で胞子の耐熱性は認め
られなかった。単胞子の着生は栄養菌糸にも観察され
た。胞子のう、菌核などの特殊構造は観察されていな
い。
Spore settlement has been confirmed only under extremely limited conditions. For example, after culturing on aerial hyphae grown on tyrosine agar diluted to 1/4 concentration at 28 ° C for about 1 month, green monospores are observed. Spores were collected and settled. Spore size is 1.0 to 1.2 in diameter
The micron was almost spherical, the surface was smooth, no motility was observed, and the heat resistance of spores was not recognized in the survival test in 100 ° C boiling water. Monospore settlement was also observed in vegetative mycelia. No special structures such as sporangia and sclerotia have been observed.

II.各種培地上の生育状態 Al-R2397株の各種培地上の生育状態は次表に示す通りで
ある。色の記載について( )内に示す標準はコンテイ
ナー・コーポレーション・オブ・アメリカ(Container C
orporation of America)社製の「カラー・ハーモニィー
・マニアル(Color Harmony Manual)」に記載のものを用
いた。観察は28℃で14〜30日培養後に行なった。(37℃
の培養性状も下記と同様だった。) III.生理的性質 (1)生育温度範囲:28℃〜55℃の温度範囲で生育し、
35℃〜45℃で良好に生育する。
II. Growth conditions on various media The growth conditions of the Al-R2397 strain on various media are shown in the following table. Regarding the color description, the standard shown in () is for Container C of America.
The one described in "Color Harmony Manual" manufactured by the Corporation of America was used. The observation was performed after culturing at 28 ° C for 14 to 30 days. (37 ° C
The culture properties of were also the same as below. ) III. Physiological properties (1) Growth temperature range: Grows in a temperature range of 28 ° C to 55 ° C,
It grows well at 35 ° C to 45 ° C.

(2)ゼラチンの液化:陰性 (3)スターチの加水分解:陽性 (4)硝酸塩の還元:陰性 (5)脱脂乳のペプトン化:陽性 脱脂乳の凝固:陰性 (6)耐塩性:1.5%NaCl添加寒天培地上でよく生育。
3%NaClでわずかに生育。4%以上では生育しない。
(2) Gelatin liquefaction: Negative (3) Starch hydrolysis: Positive (4) Nitrate reduction: Negative (5) Skim milk peptonization: Positive Skim milk coagulation: Negative (6) Salt tolerance: 1.5% NaCl Grows well on added agar medium.
Grow slightly with 3% NaCl. It does not grow above 4%.

(7)メラニン様色素の生成:陰性 IV.炭素源の利用性 (1)利用する:D−グルコース、D−フラクトース、
D−キシロース、グリセロール、L−アラビノース、D
−マンニトール、ラフィノース (2)利用しない:i−イノシトール、L−ラムノー
ス、シュークロース V.細胞壁組成 全菌体加水分解中のアミノ酸としてDL型ジアミノピメリ
ン酸を有する。糖としてアラビノース、キシロースは、
ほとんど認められず、マジュロースの存在は、不明瞭で
ある。
(7) Formation of melanin-like pigment: negative IV. Utilization of carbon source (1) Utilization: D-glucose, D-fructose,
D-xylose, glycerol, L-arabinose, D
-Mannitol, raffinose (2) Not used: i-inositol, L-rhamnose, sucrose V.I. Cell wall composition It has DL-type diaminopimelic acid as an amino acid during whole cell hydrolysis. Arabinose and xylose as sugars are
Almost unrecognized, the presence of majurose is unclear.

以上の通り、Al-R2397株は、形態的性質、生理的性質お
よび菌体の化学分析結果などから判断し、サーモモノス
ポラ・エスピー(Thermomonospora sp.)Al-R2397と同定
した。
As described above, the Al-R2397 strain was identified as Thermomonospora sp. Al-R2397 by judging from morphological properties, physiological properties, results of chemical analysis of bacterial cells and the like.

なお本菌株は、工業技術院微生物工業技術研究所に微工
研菌寄第8802号(FERM P-8802)として寄託されている。
This strain has been deposited at the Institute of Microbial Science and Technology of the Institute of Industrial Science and Technology as Microorganism Research Institute No. 8802 (FERM P-8802).

Al-R2397株は他の放線菌の場合に見られるように、その
性状が変化しやすい。例えば、Al-R2397株の、またはこ
の株に由来する突然変異株(自然発生または誘発性)、
形質接合体または遺伝子組換え体であっても、抗生物質
Al-R2397物質を生産するものは全て本発明に使用出来
る。本発明の方法では、前記の菌を通常の微生物が利用
しうる栄養物を含有する培地で培養する。栄養源として
は、グルコース、水あめ、デキストリン、シュクロー
ス、澱粉、糖みつ、動・植物油等を使用できる。また窒
素源として、大豆粉、小麦はい芽、コーンスティープリ
カー、綿実かす、肉エキス、ペプトン、酵母エキス、硫
酸アンモニウム、硝酸ソーダ、尿素等を使用できる。そ
の他、必要に応じ、ナトリウム、カリウム、カルシウ
ム、マグネシウム、コバルト、塩素、燐酸、硫酸、及び
その他のイオンを生成することができる無機塩類を添加
することは有効である。また菌の発育を助け、抗生物質
Al-R2397物質の生産を促進するような有機および無機物
を適当に添加することができる。培養法としては、好気
的条件での培養法、特に深部培養法が最も適している。
培養に適当な温度は28〜55℃であるが、多くの場合、28
〜37℃付近で培養する。抗生物質Al-R2397物質の生産は
培地や培養条件により異なるが、振とう培養、タンク培
養とも通常3〜10日の間でその蓄積が最適に達する。培
養物中の抗生物質Al-R2397物質の蓄積量が最高になった
時に培養を停止し、培養液から目的物質を単離精製す
る。
The Al-R2397 strain is likely to change its properties as seen in other actinomycetes. For example, the Al-R2397 strain, or a mutant strain (natural or inducible) derived from this strain,
Antibiotics, whether transzygous or recombinant
Anything that produces Al-R2397 material can be used in the present invention. In the method of the present invention, the above-mentioned bacterium is cultivated in a medium containing nutrients that can be utilized by ordinary microorganisms. As a nutrient source, glucose, starch syrup, dextrin, sucrose, starch, molasses, animal / vegetable oil, etc. can be used. As the nitrogen source, soybean flour, wheat germ, corn steep liquor, cottonseed meal, meat extract, peptone, yeast extract, ammonium sulfate, sodium nitrate, urea and the like can be used. In addition, it is effective to add inorganic salts capable of generating sodium, potassium, calcium, magnesium, cobalt, chlorine, phosphoric acid, sulfuric acid, and other ions, if necessary. It also helps the growth of bacteria
Organic and inorganic substances which promote the production of Al-R2397 material can be added appropriately. As the culturing method, the culturing method under aerobic conditions, especially the submerged culturing method is most suitable.
A suitable temperature for culturing is 28-55 ° C, but in most cases 28
Incubate at ~ 37 ° C. The production of the antibiotic Al-R2397 varies depending on the medium and culture conditions, but the accumulation generally reaches optimum within 3 to 10 days in both shaking culture and tank culture. When the accumulated amount of the antibiotic Al-R2397 substance in the culture reaches the maximum, the culture is stopped, and the target substance is isolated and purified from the culture solution.

本発明のAl-R2397物質の検定にあたってはマウス白血病
細胞(P-388)に対する細胞障害性の測定及び検定菌とし
てクリプトコッカス・ネオフォルマンスM9010(Cryptoco
ccus neoformans M9010)を用いる。寒天培地上の生育阻
止円径は30〜300μg/mlにおいて、濃度の対数と直線関
係を示し、14〜25mmの阻止円を与える。
In the assay of the Al-R2397 substance of the present invention, Cryptococcus neoformans M9010 (Cryptoco) as a measurement and assay strain for cytotoxicity against mouse leukemia cells (P-388)
ccus neoformans M9010) is used. When the diameter of the growth inhibition circle on the agar medium is 30 to 300 μg / ml, it shows a linear relationship with the logarithm of the concentration and gives an inhibition circle of 14 to 25 mm.

本発明より得られたAl-R2397物質は中性の脂溶性物質で
あるので、培養物からAl-R2397物質の単離、精製にあた
っては、その特性を利用して行なうことができる。即
ち、アンバーライトXAD-2(ローム・アンド・ハース社
製),ダイヤイオンHP-20(三菱化成社製)等の合成吸
着剤、セファデッックスLH-20(ファルマシア社製)、
トヨパールHW-40(東洋曹達社製)等のゲル濾過剤、シ
リカゲル、アルミナ等によるシリカゲルクロマトグラフ
ィー、酢酸エテル、クロロホルム等による溶媒抽出法、
更にメタノール等を溶媒とする結晶化法等が有効であ
る。
Since the Al-R2397 substance obtained from the present invention is a neutral fat-soluble substance, its characteristics can be used for the isolation and purification of the Al-R2397 substance from the culture. That is, synthetic adsorbents such as Amberlite XAD-2 (made by Rohm and Haas), Diaion HP-20 (made by Mitsubishi Kasei), Sephadex LH-20 (made by Pharmacia),
Toyopearl HW-40 (manufactured by Toyo Soda Co., Ltd.), gel filter, silica gel, silica gel chromatography with alumina, solvent extraction method with ether acetate, chloroform, etc.
Further, a crystallization method using methanol or the like as a solvent is effective.

以上のような方法により、あるいはこれらを適宜組合わ
せることにより、高純度のAl-R2397物質が得られる。得
られたAl-R2397物質の物理化学的性状は、次のとおりで
ある。
A highly pure Al-R2397 substance can be obtained by the method described above or by appropriately combining them. The physicochemical properties of the obtained Al-R2397 substance are as follows.

(イ)分子式および元素分析値:C31H41N2O8Cl 炭素 61.19% 水素 6.80% 窒素 4.53% 塩素 6.03% (ロ)分子量: 604(FD-MSにおいてM/Z605(M+1)を観測した。) (ハ)融点: 208〜211℃ (ニ)比旋光度: 〔α〕 23=−69.7°(c0.1,メタノール) (ホ)紫外線吸収スペクトル: メタノール溶液中で測定したスペクトルを第1図に示
す。221nm(ε37,730),240nm(sh.ε28,790),283nm(ε
2,400)に吸収極大を観測した。
(A) Molecular formula and elemental analysis value: C 31 H 41 N 2 O 8 Cl carbon 61.19% hydrogen 6.80% nitrogen 4.53% chlorine 6.03% (b) molecular weight: 604 (M / Z605 (M + 1) in FD-MS (C) Melting point: 208 to 211 ° C. (D) Specific rotation: [α] D 23 = -69.7 ° (c0.1, methanol) (V) UV absorption spectrum: spectrum measured in methanol solution Is shown in FIG. 221nm (ε37,730), 240nm (sh.ε28,790), 283nm (ε
The absorption maximum was observed at 2,400).

(ヘ)赤外線吸収スペクトル: 臭化カリウム錠で測定したスペクトルを第2図に示す。(F) Infrared absorption spectrum: The spectrum measured with a potassium bromide tablet is shown in FIG.

(ト)水素核核磁気共鳴スペクトル(重ジメチルスルホ
キシド,400MHz)ppm: 0.94(3H,d),1.07(6H,d),1.55(3H,brs), 1.84(3H,s),3.22(3H,s),3.88(3H,s), 5.28(1H,dd),その他 (チ)溶解性: ジメチルスルホキシド,メタノールに可溶; アセトン,酢酸エチル,クロロホルムに難溶; 水,n-ヘキサンに不溶 (リ)呈色反応: 過マンガン酸カリウム,グレイグ・リーバック試薬,10
%硫酸,モリブデン酸試薬に陽性;ニンヒドリン試薬に
陰性 (ヌ)薄層クロマトグラフィー(メルクシリカゲルプレ
ート,0.25mm); a)展開溶媒:クロロホルム−メタノール(10:1) Rf0.69 b)展開溶媒:トルエン−アセトン(2:1) Rf0.29 (ル)外観:無色 板状結晶 発明の効果 本発明によるAl-R2397物質は抗腫瘍活性を示し、そのマ
ウス白血病細胞(P-388)に対する50%阻害濃度は4pg/ml
以下であった。本物質の延命効果は後記の試験例に示し
た。またAl-R2397物質は抗真菌活性を示し、その各種の
真菌に対する抗真菌スペクトルは第1表に示すとおりで
ある。Al-R2397物質の各濃度のメタノール溶液をペーパ
ーディスクに20μlずつしみ込ませ、寒天平板法で測定
した阻止円の直径で示した。
(G) Hydrogen nuclear magnetic resonance spectrum (heavy dimethyl sulfoxide, 400MHz) ppm: 0.94 (3H, d), 1.07 (6H, d), 1.55 (3H, brs), 1.84 (3H, s), 3.22 (3H, s), 3.88 (3H, s), 5.28 (1H, dd), others (h) Solubility: Soluble in dimethyl sulfoxide, methanol; sparingly soluble in acetone, ethyl acetate, chloroform; insoluble in water, n-hexane ( I) Color reaction: Potassium permanganate, Greig Reebuck reagent, 10
% Sulfuric acid, Molybdic acid reagent positive; Ninhydrin reagent negative (N) Thin layer chromatography (Merck silica gel plate, 0.25 mm); a) Developing solvent: Chloroform-methanol (10: 1) Rf0.69 b) Developing solvent: Toluene-acetone (2: 1) Rf0.29 (L) Appearance: colorless plate crystals Effect of the invention The Al-R2397 substance according to the present invention exhibits antitumor activity and its 50% inhibition against mouse leukemia cells (P-388) Concentration is 4pg / ml
It was below. The life prolonging effect of this substance is shown in the test examples described below. The Al-R2397 substance exhibits antifungal activity, and the antifungal spectrum against various fungi is as shown in Table 1. 20 μl of each concentration of the Al-R2397 substance in methanol was soaked in a paper disk, and the diameter of the inhibition circle was measured by the agar plate method.

上記の結果から明らかなように、Al-R2397物質は真菌に
対し抗菌作用を示し、真菌治療剤としての有用性も期待
される。
As is clear from the above results, the Al-R2397 substance exhibits an antibacterial action against fungi and is expected to be useful as a fungal therapeutic agent.

実施例 以下に本発明の実施例を示すが、これらは単なる一例で
あって本発明を限定するものではない。ここに例示しな
かった多くの変法あるいは修飾手段を用いうることは勿
論のことである。
Examples Examples of the present invention will be shown below, but these are merely examples and do not limit the present invention. Of course, many modified or modified means not exemplified here can be used.

実施例 種培地として、スターチ2.0%、グルコース1.0%、小麦
胚芽0.6%、ポリペプトン0.5%、酵母エキス0.3%、大
豆粉0.2%、炭酸カルシウム0.1%を含む培地を用いた。
Examples As a seed medium, a medium containing 2.0% starch, 1.0% glucose, 0.6% wheat germ, 0.5% polypeptone, 0.3% yeast extract, 0.2% soybean flour, and 0.1% calcium carbonate was used.

また、生産培地として、水飴1.0%、スターチ1.0%、大
豆粉1.5%、サングレインF2 1.0%、炭酸カルシウム0.2
%、硫酸マグネシウム(7水塩)0.1%、硫酸第1鉄
(7水塩)0.0005%、塩化コバルト(6水塩)0.0005
%、を含む培地を用いた。
As a production medium, starch syrup 1.0%, starch 1.0%, soybean flour 1.5%, sun grain F2 1.0%, calcium carbonate 0.2
%, Magnesium sulfate (heptahydrate) 0.1%, ferrous sulfate (heptahydrate) 0.0005%, cobalt chloride (hexahydrate) 0.0005
%, Was used.

なお、殺菌前pHはすべてpH7.0に調製して使用した。前
記種培地20mlを分注した100ml容三角フラスコを120℃で
30分間殺菌し、これにサーモモノスポラAl-R2397(FERM
P-8802)の斜面培養の3〜4白金耳を接種し、28℃で4
日間振盪培養し、第1種培養とした。ついで種培地80ml
を分注した500ml容三角フラスコを120℃で30分間殺菌
し、前記第1種培養5mlを接種し、28℃で2日間振盪培
養し、これを第2種培養とした。さらに種培地1を分
注した5容三角フラスコを120℃で30分間殺菌し、第
2種培養50mlを接種し、28℃1日間振盪培養し、これを
第3種培養とした。
The pH before sterilization was adjusted to pH 7.0 and used. A 100 ml Erlenmeyer flask into which 20 ml of the seed medium was dispensed was placed at 120 ° C.
Sterilize for 30 minutes and add to it Thermo Monospora Al-R2397 (FERM
P-8802) Slope culture 3-4 platinum loops were inoculated and incubated at 28 ° C for 4
The culture was performed for 1 day with shaking to obtain a first seed culture. Then 80 ml of seed medium
The 500 ml Erlenmeyer flask into which was dispensed was sterilized at 120 ° C. for 30 minutes, 5 ml of the first seed culture was inoculated, and the mixture was shake-cultured at 28 ° C. for 2 days, and this was designated as the second seed culture. Furthermore, the 5-volume Erlenmeyer flask into which the seed medium 1 was dispensed was sterilized at 120 ° C. for 30 minutes, 50 ml of the second seed culture was inoculated, and the mixture was shake-cultured at 28 ° C. for 1 day, and this was designated as the third seed culture.

予め120℃30分間殺菌した35の生産培地を含む、50
容ジャーファーメンターに前記の第3種培養1を接種
し、28℃5日間通気(20/分)、攪拌初期250rpm、41
時間以降350rpm)培養した。培養終了後、濾過助剤とし
て珪藻土を加えて濾過した。得られた培養濾液85と、
菌体を50%アセトン水40で室温1時間攪拌し、濾過し
て菌体を除いた菌体抽出液を濃縮して得られた菌体抽出
濃縮液12とを合わせ、ダイヤイオンHP-20(三菱化成
社製)4.5を充填したカラムを通過させることによ
り、有効成分を吸着させた。引き続き、カラムを脱イオ
ン水70にて水洗後、有効成分を50%アセトン水にて溶
出した。
Includes 35 production media sterilized at 120 ° C for 30 minutes, 50
A jar fermenter was inoculated with the above-mentioned third seed culture 1, aerated at 28 ° C. for 5 days (20 / min), and initially stirred at 250 rpm, 41
After the time, 350 rpm). After the completion of the culture, diatomaceous earth was added as a filter aid and the mixture was filtered. The obtained culture filtrate 85,
The microbial cells were stirred with 50% acetone water 40 at room temperature for 1 hour, filtered to remove the microbial cells, and the microbial cell extract concentrate was combined with 12 to obtain DIAION HP-20 ( The active ingredient was adsorbed by passing through a column packed with 4.5 (manufactured by Mitsubishi Kasei). Subsequently, the column was washed with deionized water 70 and the active ingredient was eluted with 50% acetone water.

活性画分を集め、減圧下、アセトンを留去して15と
し、これを酢酸エチル15で抽出した後、酢酸エチル層
を無水硫酸ナトリウムで脱水して、減圧下濃縮し、16g
の油状物質を得た。得られた油状物質を珪そう土16gに
まぶし、一夜減圧下乾燥後、クロロホルムで充填したシ
リカゲルC−200(和光純薬工業社製)700mlの塔の上に
のせ、クロロホルム、次いでクロロホルム−メタノール
混液(100:1)で洗浄後、クロロホルム−メタノール混液
(50:1)にて展開するクロマトグラフィーを行った。展
開液はシリカゲル薄膜クロマトグラフィー(メルク社
60F254 5714、展開溶媒:クロロホルム−メタノール(1
0:1))を行ない、Rf値、0.69を示し、かつ第1図に示し
たような紫外部吸収スペクトルをもつ分画を集め、減圧
下に濃縮乾固して933mgの油状物質を得た。この油状物
質を少量のメタノールに溶解し、メタノールにて充填し
たセファデックスLH-20(ファルマシア社製)1の塔
にのせ、メタノールにて展開してクロマトグラフィーを
行った。活性画分を減圧下濃縮乾固し、335mgの油状物
質を得た。この油状物質を少量のメタノールに溶解し、
16時間室温に放置したところ、Al-R2397物質の無色結晶
94.1mgが得られた。このうち、20mgを熱メタノール20ml
に溶解し、減圧下メタノールを除去した後、残渣にエタ
ノールを加えて、室温放置し、再結晶させ、Al-R2397物
質の無色板状晶18mgを得た。本物質は前記の理化学的特
性を有する。さらにこの結晶をX線結晶回析に付して、
Al-R2397物質の構造を確立した。
The active fractions were collected, and acetone was distilled off under reduced pressure to 15 and this was extracted with ethyl acetate 15. The ethyl acetate layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 16 g.
Of oily substance was obtained. The obtained oily substance was sprinkled with 16 g of diatomaceous earth, dried overnight under reduced pressure, and placed on a 700 ml column of silica gel C-200 (manufactured by Wako Pure Chemical Industries, Ltd.) filled with chloroform, followed by chloroform and then a mixture of chloroform and methanol. After washing with (100: 1), chloroform-methanol mixture
Chromatography was performed at (50: 1). The developing solution is silica gel thin film chromatography (Merck)
60F254 5714, developing solvent: chloroform-methanol (1
0: 1)) was performed to collect fractions having an Rf value of 0.69 and an ultraviolet absorption spectrum as shown in FIG. 1, and concentrated and dried under reduced pressure to obtain 933 mg of an oily substance. . This oily substance was dissolved in a small amount of methanol, placed on a Sephadex LH-20 (Pharmacia) column 1 filled with methanol, and developed with methanol for chromatography. The active fraction was concentrated to dryness under reduced pressure to obtain 335 mg of an oily substance. Dissolve this oily substance in a small amount of methanol,
When left at room temperature for 16 hours, colorless crystals of Al-R2397 substance
94.1 mg was obtained. Of this, 20 mg is hot methanol 20 ml
After removing methanol under reduced pressure, ethanol was added to the residue, and the mixture was allowed to stand at room temperature and recrystallized to obtain 18 mg of a colorless plate crystal of Al-R2397 substance. The substance has the physicochemical properties described above. Further, this crystal was subjected to X-ray crystal diffraction,
The structure of Al-R2397 material was established.

試験例(抗腫瘍効果) 腹腔内にP-388腫瘍細胞を移植したマウスに、Al-R2397
物質を1日1回連続2日間腹腔内投与した。この延命効
果を第2表にT/C%値として表示した。
Test Example (Anti-tumor effect) Al-R2397 was administered to mice in which P-388 tumor cells were intraperitoneally transplanted.
The substance was administered intraperitoneally once a day for 2 consecutive days. This life-prolonging effect is shown in Table 2 as a T / C% value.

【図面の簡単な説明】[Brief description of drawings]

第1図はAl-R2397物質のメタノール溶液中20μg/mlの濃
度での紫外部吸収スペクトルを示し、第2図はAl-R2397
物質の臭化カリウム錠での赤外部吸収スペクトルを示
す。
Figure 1 shows the ultraviolet absorption spectrum of Al-R2397 substance in methanol solution at a concentration of 20 μg / ml, and Figure 2 shows Al-R2397.
The infrared absorption spectrum of the substance in potassium bromide tablet is shown.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 (C12P 17/18 C12R 1:01) (C12N 1/20 C12R 1:01) (72)発明者 長沢 美恵子 神奈川県横浜市港北区師岡町760 明治製 菓株式会社薬品研究所内 (72)発明者 庄村 喬 神奈川県横浜市港北区師岡町760 明治製 菓株式会社薬品研究所内 (72)発明者 瀬崎 正次 神奈川県横浜市港北区師岡町760 明治製 菓株式会社薬品研究所内─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification number Office reference number FI technical display location (C12P 17/18 C12R 1:01) (C12N 1/20 C12R 1:01) (72) Inventor Mieko Nagasawa 760 Meiji Seika Co., Ltd., Meiji Seika Co., Ltd., 760 Shimooka-cho, Kohoku-ku, Yokohama, Kanagawa Prefecture (72) Inventor Takashi Shomura 760, Shimooka-cho, Kohoku-ku, Yokohama-shi, Kanagawa Meiji Seika Co., Ltd. (72) Inventor Tadashi Sezaki Next 760 Meiji Seika Co., Ltd. Pharmaceutical Research Laboratory, 760 Shimooka-cho, Kohoku-ku, Yokohama-shi, Kanagawa Prefecture

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】下記の化学構造式を有する新規抗生物質A
1−R2397物質
1. A novel antibiotic A having the following chemical structural formula:
1-R2397 substances
【請求項2】サーモモノスポラ属に属し,抗生物質A1
−R2397物質を生産する菌を培養し,その培養物か
らA1−R2397物質を採取することを特徴とする新
抗生物質A1−R2397物質の製造法。
2. An antibiotic A1 belonging to the genus Thermomonospora.
-A method for producing a new antibiotic A1-R2397 substance, which comprises culturing a bacterium producing the R2397 substance and collecting the A1-R2397 substance from the culture.
JP61171759A 1986-07-23 1986-07-23 Novel antibiotic A1-R2397 substance and its production method Expired - Lifetime JPH0662632B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP61171759A JPH0662632B2 (en) 1986-07-23 1986-07-23 Novel antibiotic A1-R2397 substance and its production method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP61171759A JPH0662632B2 (en) 1986-07-23 1986-07-23 Novel antibiotic A1-R2397 substance and its production method

Publications (2)

Publication Number Publication Date
JPS6330492A JPS6330492A (en) 1988-02-09
JPH0662632B2 true JPH0662632B2 (en) 1994-08-17

Family

ID=15929155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61171759A Expired - Lifetime JPH0662632B2 (en) 1986-07-23 1986-07-23 Novel antibiotic A1-R2397 substance and its production method

Country Status (1)

Country Link
JP (1) JPH0662632B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111635418A (en) * 2020-06-17 2020-09-08 山东大学 Maytansinoid derivative and synthetic method and application thereof

Also Published As

Publication number Publication date
JPS6330492A (en) 1988-02-09

Similar Documents

Publication Publication Date Title
EP0132082B1 (en) Antibiotic/antitumor compounds and their production
EP0185456B1 (en) Cl-1577d and cl-1577e antibiotic/antitumor compounds, their production and use
EP0318056A2 (en) Novel antibiotics and process for preparing the same
US4954641A (en) Novel antitumor antibiotic substance and a method for production thereof
US4018972A (en) Antibacterial agents cis-BM123γ1 and cis-BM123γ2
US4550021A (en) Antitumor antibiotic 81-484 and process for its production
US5219736A (en) Process for producing 3-deacylated derivative of 16-membered macrolide antibiotic
JPH0662632B2 (en) Novel antibiotic A1-R2397 substance and its production method
JPS6010720B2 (en) Production method of antibiotic C-15003 P-4
US4847284A (en) Antifungal fermentation product and derivatives and compositions thereof
JPH06234784A (en) New antibiotic sf 2768 substance and its production
US3647776A (en) 1-hydroxy- and acetyloxy-3-(1-hexenylazoxy)-2-butanone
JP2557070B2 (en) Novel bioactive substances probestin, prostatin and method for producing the same
JPS6210048A (en) Novel physiologically active substance mh435
CA2017276C (en) Carcinostatic or antitumor antibiotic, conagenin, and production and uses thereof
EP0205981B1 (en) A novel anti-tumor and antimicrobial compound, its microbiological preparation and its use as medicament
JP2594085B2 (en) SF2575, a new antitumor antibiotic, and method for producing the same
JPH0625095B2 (en) Antibiotic SF-2415 substance and its production method
JPH09157266A (en) New antibiotic epoxynomicin a and b and their production
JPS6219599A (en) Novel macrolide antibiotic m119
JPS6348284A (en) Novel antibiotic yp-02908l-a and production thereof
JPH05168485A (en) New substance ksb-8200w and its production
JPS62138196A (en) Anthracyclin compound and production thereon
JPS6240293A (en) Novel antibiotic substance sf-2381a and sf-2381b and production thereof
JPS6241516B2 (en)